Abbott Laboratories ABT recently received FDA approval for its Eterna spinal cord stimulation (SCS) system for treating chronic pain. The Eterna SCS system is the smallest implantable, rechargeable ...

Credit: Shutterstock. Study participants suffered from chronic back pain for an average of 12.8 years. The Food and Drug Administration (FDA) has expanded the approval of Abbott’s spinal cord ...

It was originally approved in 2019 for the treatment of chronic pain. The Food and Drug Administration (FDA) has approved the Proclaim™ XR spinal cord stimulation (SCS) system for the treatment of ...

Abbott has obtained FDA clearance of its Eterna spinal cord stimulation (SCS) system for the treatment of chronic pain. The system is the smallest implantable, rechargeable SCS — thin wires placed ...

The new indication for Abbott's Proclaim™ XR SCS system provides a non-medication option for people with painful diabetic peripheral neuropathy Spinal cord stimulation is proven to be more effective ...

Please provide your email address to receive an email when new articles are posted on . Abbott has announced the FDA expanded the indication of its BurstDR spinal cord stimulation devices for treating ...

Abbott developed Eterna based on extensive studies with patients, physicians and caregivers to understand the unmet needs of people living with chronic pain. The studies found that people wanted a ...

The US Food and Drug Administration (FDA) has approved expanded MRI labeling for Abbott Laboratories' Eterna spinal cord stimulation (SCS) system, which will allow for higher-quality scan images for ...

Abbott is putting the old adage that “good things come in threes” to the test, with its fourth FDA approval in less than a year for its spinal cord stimulation (SCS) systems. The latest regulatory nod ...

Abbott has touted the potential of its neuromodulation portfolio in reducing patient and healthcare burdens associated with chronic pain following the positive results of three five-year analyses. The ...